Eliminate Anal Fissure Pain with DoseRite
The key to anal fissure pain relief is maintaining a relaxed internal anal sphincter muscle. This will stop the vicious anal fissure cycle, resulting in reduced pain, more comfortable bowel movements, and improved blood flow to the area, which promotes healing.
Keep the internal sphincter muscle relaxed by applying topical medications such as Diltiazem, Nifedipine or Nitroglycerine to the tissue surrounding the anal sphincter muscle (anoderm) in the anal canal.¹ Studies show that applying these medications in the anal canal is more effective at relaxing the internal sphincter muscle than application around the outside of the anus.² Delivery into the rectum should also be avoided for effective relief.
Read more about the benefit of using DoseRite in these publications, Diseases of the Colon and Rectum and Nature.
Targeted Delivery of Medication
DoseRite’s patented applicator provides a painless and straightforward way for patients to apply medication inside the anal canal. The applicator’s side-slotted design ensures medication is applied directly to the anal mucosa (anoderm) in the anal canal for maximum absorption by the internal sphincter muscle. Using DoseRite three times per day provides prolonged relaxation of the anal sphincter muscle and significant pain relief.²
1. DoseRite is available on Amazon.com for patients who already have their anal fissure medication.
2. DoseRite is also available at participating compounding pharmacies. Contact us to find a participating pharmacy near you.
3. For orders in the UK, please visit our supplier website: APR Medtech.
4. For orders in Australia, please visit our supplier website: Profile Medical Devices.
1. Stewart, D. et al, Clinical Practice Guidelines for the Management of Anal Fissures. Diseases of the Colon & Rectum Volume 60: 1 (2017) 9. DOI: 10.1097/DCR.0000000000000735
2. Torrabadella L., Salgado G., Controlled Dose Delivery in Topical Treatment of Anal Fissure: Pilot Study of a New Paradigm. Dis Colon Rectum 2005; 49: 865–868. DOI: 10.1007/s10350-005-0270-y